Media inquiries only, please contact Andrea Hofelich via email or phone, 202-827-2078.
A study, believed to the first of its kind, focused on exploring the prevalence and characteristics of both public and non-public value-based agreements in order to better understand current activity in value-based contracting. It was conducted by Duke-Margolis and NPC and published in The American Journal of Managed Care.
Richard H. Bagger, Executive Vice President, Corporate Affairs and Market Access, Celgene Corporation, has been elected Chair of the National Pharmaceutical Council’s Board of Directors for 2018-2019.
National Pharmaceutical Council and Duke-Margolis Center for Health Policy Announce New Health Policy Fellow ( )
The National Pharmaceutical Council and Duke University's Robert J. Margolis, MD, Center for Health Policy announced that Taruja Karmarkar, PhD, has been named the 2018-20 post-doctoral health policy fellow.
Study of U.S. Commercial Health Plans Shows Widespread Variation in Coverage and Reimbursement for Specialty Medicines ( )
(July 9, 2018, Washington, DC)—A new study published in the July issue of Health Affairs shows that insurance coverage and reimbursement for specialty medications var
Survey research, published in the Journal of Managed Care & Specialty Pharmacy, notes the substantial impact that biopharmaceutical innovation has had on health outcomes, particularly in the treatment of HIV, chronic obstructive pulmonary disease (COPD) and depression.
The National Pharmaceutical Council, a health policy research organization based in Washington, D.C., today welcomed four biopharmaceutical companies to its growing membership roster. They include AstraZeneca, Gilead Sciences, Horizon Pharma plc. and Spark Therapeutics, Inc.